Venetoclax: How a “Molecular Off-Switch” Is Changing Blood Cancer Treatment

How blocking BCL-2 allows blood cancer cells to restart their own self-destruct programme

Venetoclax blood cancer treatment showing how BCL-2 inhibition allows cancer cells to restart apoptosis

⏱ In 30 Seconds

✓ Venetoclax is a targeted medicine that blocks BCL-2, a survival protein used by some blood cancers.
✓ By inhibiting BCL-2, Venetoclax helps cancer cells restart apoptosis, their natural self-destruct programme.
✓ It is used in adults with CLL/SLL and in selected older or medically unfit adults with newly diagnosed AML.
✓ Venetoclax-based combinations have helped make fixed-duration treatment possible for many people with CLL.
✓ Because it can kill large numbers of cancer cells rapidly, treatment must be carefully managed to reduce the risk of tumour lysis syndrome.

A Personal Note

I recently came across a blog where people living with blood cancer and their families were sharing their experiences. Reading their stories made me think about what a drug like Venetoclax can mean to them—not simply as another cancer medicine, but as a source of hope.

At the same time, I found myself wanting to explain how this remarkable drug actually works. The biology behind Venetoclax is fascinating, but the basic idea is surprisingly simple: it blocks a survival mechanism that cancer cells depend on and allows their own cell-death programme to restart. That was one of the reasons I wanted to write this article.

If you follow oncology news, you have probably come across Venetoclax, sold in the United States under the brand name Venclexta.

It is now an important targeted treatment for several blood cancers. But what makes Venetoclax particularly interesting is how it works.

Traditional chemotherapy broadly damages rapidly dividing cells. Venetoclax instead targets BCL-2, a survival protein on which some cancer cells have become unusually dependent.

Blocking that protein does not introduce a completely new way of killing the cancer cell. It removes one of the mechanisms keeping the cell alive, allowing its existing cell-death machinery to function again.

That mechanism also explains the name of the drug. Venetoclax belongs to a wider system of medicine-name stems discussed in why many drug names end in “-mab,” “-nib” or “-clax”.

The Basic Idea: Cancer Cells That Refuse to Die

Every cell in the body contains machinery for a controlled form of death called apoptosis.

Apoptosis removes cells that are damaged, dangerous or no longer needed without causing the uncontrolled inflammation associated with accidental cell death.

Cancer cells frequently survive by disabling this process.

Rather than merely growing too quickly, they also become unusually resistant to signals telling them to die.

One of the proteins they can exploit is BCL-2.

BCL-2 normally helps regulate the balance between cell survival and cell death. In several blood cancers, however, malignant cells become highly dependent on BCL-2 to remain alive.

The protein acts like a molecular shield, restraining the pro-death proteins that would otherwise damage the mitochondria and trigger apoptosis.

How Venetoclax Blocks BCL-2

Venetoclax belongs to a class of medicines known as BH3 mimetics.

It was designed to imitate the activity of naturally occurring pro-apoptotic proteins that bind to BCL-2.

When Venetoclax occupies the binding pocket on BCL-2, the survival protein can no longer restrain the cell’s death machinery effectively.

Pro-apoptotic proteins are released, the mitochondrial membrane becomes permeable and a cascade of molecular events activates the cell’s self-destruction programme.

How Venetoclax blocks BCL-2 in cancer cells, allowing pro-apoptotic proteins to trigger mitochondrial apoptosis

Watch a biomedical animation explaining apoptosis and how Venetoclax kills cancer cells .

Which Blood Cancers Is Venetoclax Used to Treat?

Venetoclax was first approved by the US Food and Drug Administration in 2016. Its approved uses and combination regimens have expanded since then.

Chronic Lymphocytic Leukaemia and Small Lymphocytic Lymphoma

Venetoclax is used to treat adults with chronic lymphocytic leukaemia, or CLL, and small lymphocytic lymphoma, or SLL.

It may be used alone or as part of a combination regimen, depending on the patient’s treatment history, genetic risk factors and overall health.

Common partners include medicines that target other survival pathways in CLL, such as anti-CD20 antibodies and BTK inhibitors.

Acute Myeloid Leukaemia

Venetoclax is also used in combination regimens for selected adults with newly diagnosed acute myeloid leukaemia, or AML.

These regimens are intended particularly for adults aged 75 or older, or for those whose other health conditions make intensive induction chemotherapy unsuitable.

Combination partners may include azacitidine, decitabine or low-dose cytarabine, depending on the approved regimen and clinical circumstances.

A New All-Oral Combination for CLL

In February 2026, the FDA approved Venetoclax in combination with the BTK inhibitor acalabrutinib for adults with CLL or SLL.

The approval was supported by results from the Phase 3 AMPLIFY study.

The combination is important because it provides an all-oral, fixed-duration treatment option.

Patients take tablets rather than receiving the complete regimen through repeated intravenous infusions, and the therapy has a planned endpoint rather than continuing indefinitely.

The choice of treatment still depends on factors such as disease biology, genetic findings, other medical conditions and the individual patient’s preferences.

Why Fixed-Duration Treatment Matters

Many earlier targeted treatments for CLL were taken continuously until the disease progressed or unacceptable side effects developed.

Continuous therapy can control the cancer effectively, but it also means years of treatment, ongoing monitoring, cumulative side effects and financial burden.

Venetoclax-based regimens helped move the field towards time-limited treatment.

Patients complete a defined course and then enter a treatment-free monitoring period.

The aim is to produce a deep remission, often measured partly through very low or undetectable levels of measurable residual disease, while allowing patients meaningful time away from therapy.

For someone living with a chronic and generally incurable blood cancer, having a defined finish line can substantially change the experience of treatment.

The Double-Edged Sword: Tumour Lysis Syndrome

The same rapid cancer-cell killing that makes Venetoclax effective also creates one of its most important risks.

Tumour lysis syndrome, or TLS, can occur when many cancer cells break apart over a short period.

Their contents enter the bloodstream and may cause dangerous changes in potassium, phosphate, calcium and uric acid.

Severe TLS can damage the kidneys, disrupt the heart rhythm and become life-threatening.

For this reason, Venetoclax is not simply started at the full treatment dose in CLL or SLL.

Patients generally follow a gradual dose ramp-up, beginning at a low dose and increasing over several weeks.

Before and during treatment, the care team may assess:

The amount of disease present
The size of enlarged lymph nodes
Blood lymphocyte counts
Kidney function
Hydration and blood chemistry

Patients at greater risk may require more intensive monitoring, intravenous fluids or hospital observation during early doses.

Other Important Safety Considerations

Venetoclax can suppress normal blood-cell production as well as kill malignant cells.

Important adverse effects can include:

Neutropenia and increased infection risk
Anaemia
Low platelet counts
Nausea, diarrhoea or constipation
Fatigue
Embryo-fetal toxicity

Venetoclax also has clinically important interactions with medicines that affect the CYP3A enzyme system.

Patients should therefore ensure that their oncology team knows about all prescription medicines, over-the-counter drugs and supplements they are taking.

Why Resistance Can Develop

Venetoclax is highly effective in cancers that depend strongly on BCL-2, but cancer cells can evolve.

Some acquire changes in BCL-2 that reduce drug binding.

Others become more dependent on alternative survival proteins, such as MCL-1 or BCL-XL.

Cancer-cell metabolism, mitochondrial function and interactions with the surrounding tissue environment may also change.

This is one reason Venetoclax is frequently combined with other medicines.

By attacking the cancer through more than one pathway, combination therapy may deepen the response and make it harder for resistant cells to survive.

Why This Still Matters

Venetoclax provided a way to treat cancer by exploiting a specific survival dependency rather than broadly attacking rapidly dividing cells.

That principle grew from decades of research into apoptosis and BCL-2, including discoveries made at WEHI. The broader story of how that biology was translated into a medicine is explored in the Australian discovery story behind Venetoclax.

Venetoclax is not suitable for every patient, resistance can emerge and serious adverse effects require careful management. But its success demonstrated something important: sometimes the vulnerability needed to kill a cancer cell is already inside it.

Continue Reading

This article is intended for general educational purposes and is not medical advice. Anyone considering or receiving Venetoclax should rely on guidance from their oncology team, which can account for the specific diagnosis, treatment plan, health history and other medicines being used.

thebiostories

Venetoclax: The BCL-2 Inhibitor Changing Blood Cancer Treatment